KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non Operating Income: 2009-2024

Historic Non Operating Income for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$981.0 million.

  • Teva Pharmaceutical Industries' Non Operating Income rose 12.87% to -$237.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$932.0 million, marking a year-over-year increase of 7.91%. This contributed to the annual value of -$981.0 million for FY2024, which is 7.19% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Non Operating Income stood at -$981.0 million for FY2024, which was up 7.19% from -$1.1 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Non Operating Income high stood at -$834.0 million for FY2020, and its period low was -$1.1 billion during FY2021.
  • In the last 3 years, Teva Pharmaceutical Industries' Non Operating Income had a median value of -$981.0 million in 2024 and averaged -$1.0 billion.
  • Its Non Operating Income has fluctuated over the past 5 years, first fell by 26.86% in 2021, then increased by 8.70% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non Operating Income (Yearly) stood at -$834.0 million in 2020, then dropped by 26.86% to -$1.1 billion in 2021, then rose by 8.70% to -$966.0 million in 2022, then decreased by 9.42% to -$1.1 billion in 2023, then climbed by 7.19% to -$981.0 million in 2024.